Phenpromethamine (former brand name Vonedrine), also known as N,ò-dimethylphenethylamine (MPPA, BMMPEA, ò-Me-NMPEA, ò,N-MePEA), is a sympathomimetic nasal decongestant of the phenethylamine group. It was previously marketed as a nasal inhaler from 1943 through 1960 but is no longer available. The medication is a stimulant and is banned by the World Anti-Doping Agency. It has been detected in dietary supplements starting in the 2010s.
The drug is a monoamine releasing agent (MRA) similarly to ò-phenethylamine, amphetamine, and other phenethylamines. It is the N-methyl derivative of ò-methylphenethylamine (BMPEA) and the ò-methyl derivative of N-methylphenethylamine (NMPEA). Phenpromethamine is known to act as a norepinephrineâÂÂdopamine releasing agent (NDRA), with values of 154nM for norepinephrine and 574nM for dopamine in rat brain synaptosomes, whereas serotonin was not reported.